Ahmedabad-based Concord Biotech Limited has fixed the price band at ₹705 to ₹741 per Equity Share for its maiden public offer. The initial public offering of the Company will open on Friday, 4th August, 2023, for subscription and closes on Tuesday, 8th August, 2023. Investors can bid for a minimum of 20 Equity Shares and in multiples of 20 Equity Shares thereafter.
- Issue Opens on: Friday, August 4, 2023
- Issue Closes on: Tuesday, August 8, 2023
- Price Band: ₹705 to ₹741 per Equity Share
- Face Value: ₹ 1per equity share
- Lot Size: 20 Shares
The Public Issue of face value of ₹1 per Equity Share is entirely an Offer for Sale (OFS) up to 20.92 million shares by Helix Investment Holdings Pte. Limited. The offer also includes a reservation for a subscription by eligible employees. The Company through its IPO will fetch Rs 1475.26 crore – Rs 1550.59 crore at the lower and upper end of the price band.
Concord Biotech is a global supplier of bio-pharmaceutical APIs and formulations, serving more than 70 countries, including regulated markets like the United States, Europe, Japan, and India. According to the Frost & Sullivan Report, the company holds an impressive market share of over 20% by volume in 2022 for fermentation-based API products, including mupirocin, sirolimus, tacrolimus, mycophenolate sodium, and cyclosporine. Its substantial success can be attributed to its total installed fermentation capacity of 1,250 m3 as of March 31, 2023.
Furthermore, Concord Biotech expanded its reach by venturing into the formulation business in India and emerging markets such as Nepal, Mexico, Indonesia, Thailand, Ecuador, Kenya, Singapore, and Paraguay. The company specializes in manufacturing bio-pharmaceutical APIs through fermentation and semi-synthetic processes, with a focus on therapeutic areas such as immunosuppressants, oncology, and anti-infectives. Additionally, they provide formulations for critical care in areas like immunosuppressants, nephrology drugs, and anti-infective drugs.
Concord Biotech’s outstanding achievements are evident from its diverse portfolio comprising 23 API products. The company has made significant strides in regulatory filings, having submitted 128 Drug Master Files across various countries, with substantial filings in the United States, Europe, and Japan as of June 30, 2023.
Financially, the company’s revenue from operations increasing by 19.67% to ₹853.17 crore in the Financial Year 2023 from ₹712.93 crore in the previous year. This growth is primarily attributed to increased sales volume to existing and new customers, as well as certain product price adjustments. Additionally, Concord Biotech’s profit after tax witnessed a remarkable surge of 37.24%, reaching ₹240.08 crore in the Financial Year 2023 compared to ₹174.93 crore in the Financial Year 2022.
Kotak Mahindra Capital Company Limited, Citigroup Global Markets India Private Limited, and Jefferies India Private Limited are the book running lead managers. The Equity Shares are proposed to be listed on BSE and NSE.
